Aimmune Therapeutics Completes IPO

August 5, 2015 – Aimmune Therapeutics announced today the pricing of its initial public offering at $16.00 per share. Trading is to begin tomorrow on NASDAQ under the symbol AIMT. Company press release. FLG partner: Victor Colunga.

Read More
Pan Pacific Bank Names FLG Partner Eric Hall to its Board of Directors

July 22, 2015 – Today Pan Pacific Bank Names FLG Partner Eric Hall to its Board of Directors. Press release.

Read More
Liquid Light Signs Agreement with Coca-Cola Company

July 20, 2015 – FLG client Liquid Light announced it has signed a technology development agreement with the Coca-Cola Company. Company press release. FLG partner: Chris Lowe.

Read More
Oculeve is Acquired by Allergan

July 6, 2015 –  Today FLG client Oculeve, a development stage company focused on treatments of dry eye diseases, accounted that it has agreed to be acquired by Allergen plc. Oculeve press release. FLG partner: Mark Murray.

Read More
Allergen Research Changes Its Name to Aimmune Therapeutics

FLG client Allergen Research Corporation has changed its name to Aimmune Therapeutics. Company press release.

Read More